Financial Report: Pfizer

Pfizer

2Q Revenues: $11.1 billion (-6%)

2Q Earnings: $1.3 billion (-48%)

YTD Revenues: $23.6 billion (flat)

YTD Earnings: $4.7 billion (-29%)

Comments: Worldwide pharmaceutical revenues for the quarter were $10.1 billion, down 7%. The following drugs performed well in the quarter and YTD respectively: Celebrex, 1% and 12%; Lyrica, 49% and 73%; Detrol/Detrol LA, 5% and 11%; Zyvox, 21% and 30%; Geodon/Zeldox, 8% and 14%; Caduet, 50% and 69%; Vfend, 23% and 25%; and Aromasin, 22% and 27%. 2Q revenues were hit hard by generic Zocor’s competition against Lipitor and the loss of U.S. exclusivity for Zoloft and Norvasc. Earnings were impacted by the company’s payments to Bristol-Myers Squibb regarding the apixaban collaboration.